Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q1 2025 value amounting to $10000.0.

  • Spyre Therapeutics' Non-Current Assets fell 9696.05% to $10000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $20000.0, marking a year-over-year decrease of 9800.2%. This contributed to the annual value of $10000.0 for FY2024, which is 9697.89% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Non-Current Assets of $10000.0 as of Q1 2025, which was down 9696.05% from $10000.0 recorded in Q4 2024.
  • Spyre Therapeutics' Non-Current Assets' 5-year high stood at $12.6 million during Q2 2021, with a 5-year trough of $10000.0 in Q3 2024.
  • For the 5-year period, Spyre Therapeutics' Non-Current Assets averaged around $5.9 million, with its median value being $8.1 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Non-Current Assets surged by 1603.27% in 2021, and later tumbled by 9924.01% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Non-Current Assets (Quarter) stood at $11.0 million in 2021, then decreased by 19.47% to $8.9 million in 2022, then crashed by 96.28% to $331000.0 in 2023, then tumbled by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Its last three reported values are $10000.0 in Q1 2025, $10000.0 for Q4 2024, and $10000.0 during Q3 2024.